“a favorable trend”

14.2 months; hazard ratio [HR]: 0.82; 95% confidence interval [CI]: 0.68-0.99; P = 0.039), with a favorable trend observed for progression-free survival (PFS) as well (median PFS: 10.6 vs. 9.3 months; HR: 0.85; 95% CI: 0.68-1.05; P = 0.137) 12 .

When analyzed according to the status of hepatic arterial phase, arterial phase enhancement demonstrated a favorable trend on prognosis of patients with HBV-associated ICC without statistical significance (HR, 0.435; 95% CI, 0.140 to 1.359; P = 0.141), and TACE independently improved overall survival of patients with arterial phase enhancement (HR, 0.105; 95% CI, 0.014 to 0.774; P = 0.027).

The results of the present study showed that CRT efficacy is a significant clinicopathological factor associated with DFS ( P = 0.031) and exhibits a favorable trend with OS ( P = 0.144), indicating that CRT could decrease recurrence and potentially benefit OS.

This difference was statistically significant (χ2=8.24, P = 0.004), While mortality rates showed a favorable trend in the intervention group (6.5% vs. 20.0% in controls), this difference did not reach statistical significance ( P = 0.147).

Although the reduction in pneumonia did not reach statistical significance, the antiemetic group showed a favorable trend compared with placebo (39/237 (16.5%) antiemetic, 90/278 (32.4%) placebo; mean difference 15.9%, RR = 0.44, 95% CI: 0.15–1.28, p = 0.15).

Subclassifying AEs according to enteral stent patency, no significant difference was observed in terms of stent dysfunction rate (stent migration, stent obstruction, and relapse of GOO symptoms) between the two groups although a favorable trend was observed for EUS-GE (0% vs. 11.5 %, p = 0.16).

This reduction was significantly smaller than that in bipolar coagulation group (0.29, 95% CI 0.23–0.42; P < 0.001) and showed a favorable trend compared to the suture group (0.20, 95% CI 0.11–0.25; P = 0.166; Table 4 , Fig. 2 ).

The result of meta-analysis revealed that, compared with control group, AA group had no statistically significant effect in reducing disability but a favorable trend at 4 weeks [MD = −1.99, 95% CI (−4.93, 0.95), P = 0.18] ( Figure 7 ).

The median PFS of the IO + CRT group was 6.8 months (95% CI : 5.0-10.3), showing a favorable trend (HR = 0.69; 95% CI : 0.40–1.21; P = 0.194), compared with the PFS of 3.9 months (95% CI : 2.5–7.9) in the CRT group.

Although the reduction in anxiety in the hypnotic group did not reach statistical significance, it exhibited a favorable trend ( β = –0.58, 95% CI: –1.39 to –0.22, P = 0.20).

While a higher IFNα response score showed a favorable trend toward improved EFS, this association did not reach statistical significance (HR=0.79, 95% CI 0.54 to 1.14, p=0.20; online supplemental figure S6G ).

The mutant 6.7.1 showed a favorable trend towards lower induction of proliferation (P<0.2), whereas 11.5.2 showed proliferation comparable to rFel d 1.

Although not statistically significant, a favorable trend towards an improved OS (HR 0.88; 95% CI 0.72–1.07; P=0.2086) and ORR (32.8% vs 26.7%; P=0.1201) was observed.

For patients with an NRAS mutation (five were evaluable), a favorable trend of PFS was observed; the median PFS was 9.6 months for NRAS -mutant patients versus 6.9 months for NRAS- wild-type patients (HR, 0.41; P = 0.21).

In contrast, the KEYNOTE-122 trial, which investigated pembrolizumab asmonotherapy in patients with recurrent or metastatic NPC who had previously failed platinum-based chemotherapy, did not report a significant improvement in OS in the pembrolizumab arm, despite showing a favorable trend (HR 0.9, 95% CI: 0.67–1.19, p = 0.2262).

Time-dependent cox analysis indicated that e-irAE was associated with a favorable trend in both PFS [hazard ratio (HR), 0.77; 95% CI, 0.50–1.19; P=0.24] and OS (HR, 0.84; 95% CI, 0.52–1.36; P=0.48).

However, in multivariable analysis including age, invasive tumor size, lymph node and distant metastases, hormone therapy, and surgical intervention, the association between screening and all-cause mortality was no longer statistically significant, though a favorable trend was observed (HR 0.42, p = 0.25).

OS showed a favorable trend (HR 0.703, P = 0.252).

Bcl-2 status was significant in ER-negative patients ( p = 0.010) and showed a favorable trend in ER-positive patients ( p = 0.259) (Fig. 3 ).

Although Yoga also showed a favorable trend (SMD = −0.91, 95% CI: −2.51 to −0.70), the result did not reach statistical significance ( p = 0.27).

The present study showed a favorable trend in LVEF for the suppression-type MIRI subgroup compared with the non-MIRI group (54.0±8.9% vs. 51.2±8.1%, P =0.312), but this did not achieve statistical significance.

Comparing to treating only part of metastatic lesions, total irradiation of metastatic lesions was associated with superior PFS (HR, 0.44; 95 % CI, 0.18–1.11; p = 0.083), and higher radiation doses (BED 10 ≥ 60 Gy) showed a favorable trend to improve the PFS (HR, 0.71; 95 % CI, 0.36–1.39; p = 0.319).

Although the RA group showed a favorable trend, the difference was not statistically significant (χ2(2) = 2.01, p = 0.365).

Although the associations with DSS and OS were not statistically significant, the point estimates suggested a favorable trend among those who used SGLT2 inhibitor (DSS: HR, 0.60; 95% CI, 0.20-1.85; P = .37; OS: HR, 0.70; 95% CI, 0.42-1.16; P = .17; Figure 1 C and D).

18 Although median OS was not reached in both treatment groups, a favorable trend for amivantamab plus lazertinib was observed in the Asian population (median follow-up: 22.5 months; HR 0.84; 95% CI: 0.58‒1.23; nominal p = 0.380). 33 Moreover, both of these studies included patients with asymptomatic or stable CNS metastases.